Short Interest in Pharma Mar (OTCMKTS:PHMMF) Declines By 52.8%

Pharma Mar (OTCMKTS:PHMMF) was the recipient of a large drop in short interest in August. As of August 14th, there was short interest totaling 94 shares, a drop of 52.8% from the July 30th total of 199 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 27 shares, the days-to-cover ratio is presently 3.5 days.

Pharma Mar Stock Performance

OTCMKTS PHMMF opened at $97.36 on Friday. Pharma Mar has a twelve month low of $77.41 and a twelve month high of $110.40. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. The business’s fifty day moving average is $85.95 and its 200 day moving average is $93.55.

Analyst Ratings Changes

A number of research analysts have issued reports on PHMMF shares. Zacks Research upgraded Pharma Mar to a “hold” rating in a research report on Monday, June 15th. Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy”.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.